Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
NEUROCRINE BIOSCIENCES INC director Shalini Sharp exercised restricted stock units into common stock. She acquired 1,659 shares of common stock from vested RSUs and did not sell any shares in this filing. Following the transaction, she directly holds 4,088 shares of common stock.
NEUROCRINE BIOSCIENCES INC director William H. Rastetter exercised restricted stock units into common shares. On May 21, 2026, he converted 3,318 Restricted Stock Units into 3,318 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related vesting event rather than a market purchase or sale.
After this transaction, Rastetter’s direct holdings increased to 43,678 common shares, which are held by the Rastetter Family Trust, where he has voting and investment power. The RSU award was granted on May 21, 2025 and was fully vested at the time of conversion, and no remaining derivative position is reported in this filing.
NEUROCRINE BIOSCIENCES INC director Richard F. Pops exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at an exercise price of $0.00 per share. These RSUs were granted on May 21, 2025 and were fully vested. Following the transaction, Pops directly holds 37,798 shares of Neurocrine Biosciences common stock, reflecting a routine equity compensation event with no open-market buying or selling.
NEUROCRINE BIOSCIENCES INC director Christine A. Poon exercised restricted stock units into common shares. On May 21, 2026, she converted 3,318 fully vested Restricted Stock Units into an equal number of common shares at no cash cost, with no shares sold in this filing.
The RSUs were originally granted on May 21, 2025, with each unit representing one share upon vesting. Following the conversion, she directly holds 4,753 shares of Neurocrine Biosciences common stock.
NEUROCRINE BIOSCIENCES INC director Leslie V. Norwalk exercised restricted stock units into common shares. On 2026-05-21, Norwalk converted 1,659 Restricted Stock Units into 1,659 shares of Common Stock, a routine compensation-related equity acquisition with no reported share sales.
After the transaction, Norwalk directly holds 4,088 shares of Common Stock. The RSU award being exercised was granted on May 21, 2025 and was fully vested, meaning this filing reflects the settlement of previously awarded equity rather than new market purchases or sales.
NEUROCRINE BIOSCIENCES INC director George J. Morrow exercised restricted stock units into common shares. He converted 3,318 RSUs into 3,318 shares of common stock, increasing his direct common stock holdings to 10,386 shares. The RSU award, granted on May 21, 2025, was fully vested and each unit represented one share of common stock.
NEUROCRINE BIOSCIENCES INC director Johanna Mercier exercised restricted stock units into common shares. On May 21, 2026, 3,318 Restricted Stock Units converted into 3,318 shares of common stock at a price of $0.00 per share. Following this derivative exercise, Mercier directly owns 6,853 shares of Neurocrine Biosciences common stock. The RSU award was granted on May 21, 2025 and was fully vested at the time of conversion, making this a routine compensation-related transaction rather than an open-market purchase or sale.
Neurocrine Biosciences director Gary A. Lyons exercised fully vested restricted stock units, converting 1,659 RSUs into the same number of common shares. This reflects a derivative exercise at a stated price of $0.00 per unit, typical for equity compensation.
After the transaction, Lyons directly holds 122,141 common shares, including 116,158 shares held through the Gary A. Lyons Revocable Living Trust, over which he has voting and investment power. The filing shows no share sales, only the RSU conversion into stock.
Neurocrine Biosciences director Kevin Charles Gorman reported same-day option exercises and share sales in company stock. He exercised 205,088 Non-Qualified Stock Options at $43.24 per share, converting them into common shares, and sold 245,088 common shares at a weighted average price of $154.3318 per share in open-market transactions.
The sales were carried out by a broker under a Rule 10b5-1 trading plan adopted on February 17, 2026, which company policy prevents him from amending after adoption. Following these transactions, he holds 511,293 common shares, which are held by the Gorman and Blais Family Trust, where he has voting and investment power.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell securities tied to NBIX holdings. The filing lists 40,000 previously vested RSUs/PSUs with an original date of 02/01/2020 and 205,088 shares from an exercise of stock options on 05/19/2026.
The filing shows transaction type labels including Previously Vested RSUs & PSUs and Exercise of Stock Options, and identifies NASDAQ as the market. Cash treatment is noted for the option exercise.